Chemours (CC) saw its stock price plummet 6.28% in after-hours trading on Tuesday following the release of its first-quarter 2025 financial results. The chemical company's earnings fell short of analysts' expectations, overshadowing a better-than-expected revenue performance.

The company reported adjusted earnings per share (EPS) of $0.13, significantly below the $0.21 estimated by analysts according to IBES data. This represents a substantial miss of about 38% compared to expectations. Chemours' adjusted EBITDA came in at $166 million, also falling short of the projected $171.3 million.

Despite the earnings disappointment, Chemours managed to surpass revenue estimates. The company posted sales of $1.4 billion for the quarter, exceeding the analyst consensus of $1.352 billion. However, this revenue beat was not enough to offset investor concerns about the earnings miss.

The sharp decline in Chemours' stock price reflects investor disappointment with the company's profitability for the quarter. The lower-than-expected earnings and EBITDA suggest that the company faced challenges in converting its revenue into profit, possibly due to increased costs or operational inefficiencies. This performance may raise questions about Chemours' ability to maintain its profit margins in the current economic environment.